0000000000587110
AUTHOR
J Schubert
Improved limits on the lepton-flavor violating decays tau(-) -> l(-)l(+)l(-)
A search for the neutrinoless, lepton-flavor violating decay of the tau lepton into three charged leptons has been performed using 376fb-1 of data collected at an e+e- center-of-mass energy around 10.58 GeV with the BABAR detector at the SLAC PEP-II storage rings. In all six decay modes considered, the numbers of events found in data are compatible with the background expectations. Upper limits on the branching fractions are set in the range (4-8)×10-8 at 90% confidence level. © 2007 The American Physical Society.
Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries
AbstractAimsPatients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and resultsWe used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and of…
Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.
1061 Background: BRAWO is a German non-interventional study, which enrolled more than 2400 patients (pts) with advanced/metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with EVE and EXE. Main objectives are a) the impact of physical activity on efficacy and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy when EVE is used in daily clinical practice. Methods: In this update on the results of the 3rd interim analysis (data cut-off 18-Oct-2016) we analyzed under real world conditions the first 1.078 patients followed up until disease progression for their progression-free survival (PFS) events. A two-…
Searches for B0 decays to combinations of charmless isoscalar mesons
We search for B meson decays into two-body combinations of eta, eta', omega, and phi mesons from 89 million B B-bar pairs collected with the BaBar detector at the PEP-II asymmetric-energy e+e- collider at SLAC. We find the branching fraction BF(B0 -> eta omega) = (4.0^{+1.3}_{-1.2} +- 0.4) x 10^-6 with a significance of 4.3 sigma. For all the other decay modes we set the following 90% confidence level upper limits on the branching fractions, in units of 10^-6 : BF(B0 -> eta eta)<2.8, BF(B0 -> eta eta')<4.6, BF(B0 -> eta' eta')<10, BF(B0 -> eta'omega)<2.8, BF(B0 -> eta phi)<1.0, BF(B0 -> eta' phi)<4.5, BF(B0 -> phi phi)<1.5.
Measurements of the Absolute Branching Fractions of B± →k±Xc c
A study of the two-body decays B±→XccK±, where Xcc refers to one charmonium state, is reported by the BABAR Collaboration using a data sample of 424 fb-1. The absolute determination of branching fractions for these decays are significantly improved compared to previous BABAR measurements. Evidence is found for the decay B+→X(3872)K+ at the 3σ level. The absolute branching fraction B[B+→X(3872)K+]=[2.1±0.6(stat)±0.3(syst)]×10-4 is measured for the first time. It follows that B[X(3872)→J/ψπ+π-]=(4.1±1.3)%, supporting the hypothesis of a molecular component for this resonance.
Median progression free survival (PFS) for patients treated with everolimus (EVE) plus exemestane (EXE) for HR plus mBC in routine clinical practice : Results of the 3rd interim analysis of the non-interventional trial BRAWO
e12547 Background: BRAWO is a non-interventional study, which enrolled more than 2400 patients (pts) with advanced/metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with EVE and EXE. Main objectives are a) the impact of physical activity on efficacy and quality of life, b) prophylaxis and management of stomatitis in clinical routine, and c) the sequence of therapy when EVE is used in daily clinical practice. We report updated data of the 3rd interim analysis, including PFS. Methods: This updated analysis (data cut-off 18 Oct 2016) covers data of the first 1345 documented pts with at least one follow up under therapy. Here we describe the baseline characteristics…